By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Investment firm William Blair has initiated coverage of Qiagen with a "Market Perform" rating and estimated adjusted earnings per share in 2011 of $.98 and EPS in 2012 of $1.17, after factoring in the acquisition of Cellestis announced earlier this week.

For 2011, analyst Brian Weinstein estimates Qiagen's revenues to be $1.17 billion, while in 2012 he estimates revenues will total $1.27 billion.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

May
01
Sponsored by
Horizon Discovery

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

May
15
Sponsored by
Tecan

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.